StreetInsider.com News Articles

Barclays Starts Helus Pharma (HELP) at Overweight

Fri, 18 Sep 2026 09:35:04 -0400

Barclays initiates coverage on Helus Pharma (NASDAQ: HELP) with a Overweight rating.

For an analyst ratings summary and ratings history on Helus Pharma click here. For more ratings news on Helus Pharma click here.

Shares of Helus Pharma closed at $14.02 yesterday.

Form 3 CYBIN INC. For: Sep 17 Filed by: Halstead Michael

Thu, 17 Sep 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260917/27076700.html

Form 4 CYBIN INC. For: Sep 08 Filed by: Glavine Paul

Fri, 11 Sep 2026 09:04:00 -0400

si-local-file:///var/storage/secattach/20260911/27051172.html

Form 4 CYBIN INC. For: Sep 08 Filed by: Glavine Paul

Fri, 11 Sep 2026 09:04:00 -0400

si-local-file:///var/storage/secattach/20260911/27051175.html

Form 4 CYBIN INC. For: Sep 08 Filed by: So Eric H. L.

Fri, 11 Sep 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260911/27051164.html

Form 6-K CYBIN INC. For: Sep 10

Thu, 10 Sep 2026 14:04:00 -0400

si-local-file:///var/storage/secattach/20260910/27047755.html

Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York

Thu, 10 Sep 2026 07:30:00 -0400

CEO Michael Halstead to participate in a fireside chat on Wednesday, September 16, 2026 at 8:30 a.m. EDT.

NEW YORK and TORONTO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that Michael Halstead, Helus Pharma’s Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 24^th Annual Global Healthcare Conference in New York City.

The fireside chat will be webcast live on Wednesday, September 16, 2026

Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York

Thu, 10 Sep 2026 07:30:00 -0400

CEO Michael Halstead to participate in a fireside chat on Wednesday, September 16, 2026 at 8:30 a.m. EDT.

The fireside chat will be webcast live on Wednesday, September 16, 2026

Form 4 CYBIN INC. For: Sep 04 Filed by: So Eric H. L.

Thu, 10 Sep 2026 06:22:00 -0400

si-local-file:///var/storage/secattach/20260910/27044737.html

Form 4 CYBIN INC. For: Sep 03 Filed by: Glavine Paul

Thu, 10 Sep 2026 06:19:00 -0400

si-local-file:///var/storage/secattach/20260910/27044728.html

Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York

Wed, 09 Sep 2026 07:30:00 -0400

CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. EDT

NEW YORK and TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that Michael Halstead, Helus Pharma’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York City taking place September 14-16, 2026.

The fireside chat will be webcast live

Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York

Wed, 09 Sep 2026 07:30:00 -0400

CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. EDT

The fireside chat will be webcast live

Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York

Thu, 03 Sep 2026 07:30:00 -0400

CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. EDT.

NEW YORK and TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that Michael Halstead, Helus Pharma’s Chief Executive Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference in New York City taking place September 9-11, 2026.

The fireside chat will be webcast live on Friday, September

Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York

Thu, 03 Sep 2026 07:30:00 -0400

CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. EDT.

The fireside chat will be webcast live on Friday, September

Helus Pharma (HELP) PT Raised to $62 at TD Cowen

Thu, 20 Aug 2026 06:03:25 -0400

TD Cowen analyst Ritu Baral raised the price target on Helus Pharma (NASDAQ: HELP) to $62.00 (from $8.00) while maintaining a Buy rating.

The analyst comments "We are raising our pNPV based target to $62 from $8 on three major recent value-creating tailwinds to our thesis: 1) increased visibility into Ph3 HLP003 adjunct MDD data timing, now expected mid-Nov 2026, 2) a new, seasoned CEO with an extensive operational and strategic track record in neuropsych, and 3) new M&A, regulatory and executive branch tailwinds for the psychedelic neuropsych sector."

Helus Pharma (HELP) PT Raised to $62 at TD Cowen

Thu, 20 Aug 2026 06:03:25 -0400

TD Cowen analyst Ritu Baral raised the price target on Helus Pharma (NASDAQ: HELP) to $62.00 (from $8.00) while maintaining a Buy rating.

Form D CYBIN INC.

Wed, 19 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260819/26950970.html

Form D CYBIN INC.

Wed, 19 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260819/26950970.html

Form D CYBIN INC.

Wed, 19 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260819/26950943.html

Form D CYBIN INC.

Wed, 19 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260819/26950943.html

H.C. Wainwright Reiterates Buy Rating on Helus Pharma (HELP)

Wed, 19 Aug 2026 06:48:57 -0400

H.C. Wainwright analyst Patrick R. Trucchio reiterated a Buy rating and $70.00 price target on Helus Pharma (NASDAQ: HELP).

The analyst commented: "On August 14, Helus reported F1Q27 results and reiterated that enrollment in the Phase 3 trial (APPROACH) evaluating HLP003 in major depressive disorder (MDD) is complete, with topline data on track for 4Q26. APPROACH enrolled 223 adults with moderate-to-severe MDD who had an inadequate response to background antidepressant therapy. Two recent developments incrementally de-risk the program, in our view. First, a completed drug-drug interaction (DDI) study showed no meaningful pharmacokinetic (PK) interaction across the cytochrome P450 (CYP450) enzymes examined,

Form 6-K CYBIN INC. For: Aug 18

Wed, 19 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260819/26946728.html

Form 6-K CYBIN INC. For: Aug 18

Wed, 19 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260819/26946728.html

Form 6-K CYBIN INC. For: Aug 18

Tue, 18 Aug 2026 11:43:00 -0400

si-local-file:///var/storage/secattach/20260818/26942781.html

Form 6-K CYBIN INC. For: Aug 18

Tue, 18 Aug 2026 11:43:00 -0400

si-local-file:///var/storage/secattach/20260818/26942781.html